The biology and inhibition of glucose‐regulated protein 94/gp96. Issue 6 (21st July 2022)

• Record Type: Journal Article
• Authors: Pugh, Kyler W.; Alnaed, Marim; Brackett, Christopher M.; Blagg, Brian S. J.
• Is Part Of: Medicinal research reviews. Volume 42:Issue 6(2022)
• Page Start: 2007
• Page End: 2024
• Publication Date: 2022-07-21
• Subjects: cancer -- chaperones -- glaucoma -- gp96 -- Grp94 -- Hsp90 -- immune system -- inhibitors -- mutant myocilin -- viruses; Pharmacology -- Periodicals; Drugs -- Research -- Periodicals; 615
• DOI: 10.1002/med.21915
• Languages: English
• ISSNs: 0198-6325

Abstract

Abstract: The 94 kDa molecular chaperone, glucose‐regulated protein 94 (Grp94), has garnered interest during the last decade due to its direct association with endoplasmic reticulum (ER) stress and disease. Grp94 belongs to the Hsp90 family of molecular chaperones and is a master regulator of ER homeostasis due to its ability to fold and stabilize proteins/receptors, and to chaperone misfolded proteins for degradation. Multiple studies have demonstrated that Grp94 knockdown or inhibition leads to the degradation of client protein substrates, which leads to disruption of disease‐dependent signaling pathways. As a result, small molecule inhibitors of Grp94 have become a promising therapeutic approach to target a variety of disease states. Specifically, Grp94 has proven to be a promising target for cancer, glaucoma, immune‐mediated inflammation, and viral infection. Moreover, Grp94‐peptide complexes have been utilized effectively as adjuvants for vaccines against a variety of disease states. This work highlights the significance of Grp94 biology and the development of therapeutics that target this molecular chaperone in multiple disease states.